NCT01569256

Ovarian Hyperstimulation Syndrome and Cabergoline

The Effect Of Cabergoline On Follicular Microenvironment Profile In Patients With High Risk Of Ohss

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Etlik Zubeyde Hanim Womens' Health and Teaching Hospital · Unknown
• Sex: Female
• Age: 23 Years – 35 Years
• Healthy volunteers: Accepted

Summary

Cabergoline prevents ovarian hyperstimulation syndrome in high risk patients by disrupting follicular fluid hormone microenvironmentally altering the follicular fluid levels of insulin like growth hormone -I (IGF-I), antimullerian hormone (AMH), inhibin B and hepatocyte growth factor (HGF) levels in women with PCOS and high risk of ovarian hyperstimulation syndrome (OHSS).

Detailed description

Dopamine agonists have been proposed as a prophylactic treatment for OHSS in women with high risk of OHSS, however the possible mechanism of action has not been clearly known. In experimental studies, inhibition of vascular endothelial growth factor based pathway was proposed as a possible action of mechanism of dopamine agonists. However the role hepatocyte growth factor (HGF), insulin like growth factor-I (IGF-I), inhibin B and antimullerian hormone (AMH) on cabergoline action in OHSS prevention has not been known.

Conditions

• Polycystic Ovarian Syndrome
• Ovarian Hyperstimulation Syndrome

Interventions

Type	Name	Description
DRUG	Cabergoline	Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days

Timeline

• Start date: 2008-03-01
• Primary completion: 2009-03-01
• Completion: 2009-03-01
• First posted: 2012-04-03
• Last updated: 2012-04-04